Back to top

Analyst Blog

Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) recently announced that its Korean partner, Cha Bio&Diostech, has filed its first investigational new drug (IND) application for Pluristem's PLacental eXpanded (PLX) cells with the Korean Food and Drug Administration (KFDA).

Cha Bio&Diostech is seeking the KFDA’s permission to initiate a phase II trial for the use of PLX-PAD in the treatment of intermittent claudication (IC).

We remind investors that Pluristem inked an exclusive out-license and strategic partnership agreement with Cha Bio&Diostech in Jun 2013 whereby Cha Bio&Diostech can use Pluristem's PLX cells for treating peripheral artery disease (PAD) in South Korea.

The deal is specifically for two indications – critical limb ischemia (CLI) and IC.

We note that Pluristem develops placenta-based cell therapies. As per the agreement, Cha Bio&Diostech will be responsible for conducting and sponsoring clinical trials on PLX-PAD for the potential treatment of patients suffering from CLI and IC in South Korea. The studies will be conducted under the supervision of the KFDA.

However, Pluristem will retain rights to its proprietary manufacturing technology as well as cell-related intellectual property. The company will also have rights to use the data generated from the studies conducted by Cha Bio&Diostech, to advance its PLX candidates outside South Korea.

Pluristem and Cha Bio&Diostech will form a joint venture after receiving the first regulatory approval for a PLX product in South Korea. The joint venture will market PLX cell products there.

Pluristem develops placenta-based cell therapies in collaboration with companies like United Therapeutics (UTHR - Analyst Report) or through research and clinical institutions.

Meanwhile, other companies like Celgene Cellular Therapeutics, a wholly-owned subsidiary of Celgene Corporation (CELG - Analyst Report) is conducting research on stem cells derived from the human placenta as well as from the umbilical cord for the treatment of different diseases.

Pluristem currently carries a Zacks Rank #3 (Hold). The company suffered a setback last month when the US Food and Drug Administration (FDA) placed a clinical hold on a phase II IC study following a serious allergic reaction in one of the patients who required subsequent hospitalization.

The patient was discharged the next day after the symptoms were managed.

Right now, Array BioPharma (ARRY - Snapshot Report) looks attractive with a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%